** Shares of medical device supplier Patterson Companies PDCO.O rise 7.3% to $23.47 premarket
** PDCO says it is evaluating strategic alternatives including a sale or merger to increase shareholder value
** Brokerage Leerink Partners says the review could "shine a light" on the gap between PDCO's current stock price and its historical valuations
** PDCO lowers forecast for annual adj. EPS to between $2.25 and $2.35, from prior range of $2.33 to $2.43
** Co's Q2 adj. profit of 47 cents/shr misses analysts' est. of 49 cents/shr, according to LSEG data, hurt by weaker dental equipment sales and cybersecurity attack on vendor Change Healthcare
** Co reports Q2 sales of $1.67 bln vs. est. of $1.65 bln - LSEG
** As of last close, stock has fallen 23.1% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。